Boehringer's Spiriva has advantages for patients with COPD, says IQWiG
In order to widen the narrowed airways in patients with chronic obstructive pulmonary disease (COPD), tiotropium bromide is one of the drugs available that can be prescribed for inhalation, according to the German Institute for Quality and Efficiency in Health Care (IQWiG).
The COPD drug is German family-owned drug major Boehringer Ingelheim’s blockbuster brand Spiriva, which generated first-half 2012 sales of 1.8 billion euros ($2.25 billion).
The IQWiG has examined whether tiotropium offers a perceptible advantage to patients compared to placebo and to other COPD drugs. In addition, the two currently marketed types of inhaler (HandiHaler and Respimat) for tiotropium were compared.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze